Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Positive Spin Isn’t Working for Sarepta Therapeutics

By Josh Enomoto, InvestorPlace Contributor

SRPT stock has some positives going for it but its underlying gene therapy solutions have questions that investors can’t shake.

Fisker Stock Is an Aspirational Bet That Could Be Worth Making Here

By Josh Enomoto, InvestorPlace Contributor

Like other electric vehicle investments, FSR stock has taken a beating but some compelling factors make it a speculative buy.

Aphria’s Global Ambitions Give It Some Heft Ahead of Tilray Tie-up

By Josh Enomoto, InvestorPlace Contributor

APHA stock seems like a compelling buy based on its upcoming merger with Tilray but you should look at the facts before deciding.

7 Hydrogen Stocks for a Greener Portfolio

By Josh Enomoto, InvestorPlace Contributor

While the media is devoting its attention to electric vehicles, hydrogen stocks may offer the key to a cleaner, greener future.

Analyze Senseonics Thoroughly Before You Feed the Meme

By Josh Enomoto, InvestorPlace Contributor

SENS stock is banking on an FDA approval for its diabetes sensor. However, you’ll want to analyze the fundamentals before proceeding.

Load More